Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
163.3 USD | -2.36% | +0.41% | +7.82% |
03:43pm | Sector Update: Health Care Stocks Mixed Premarket Friday | MT |
03:16pm | Well, it isn't as bad as feared... |
Business Summary
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Number of employees: 50,000
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Immunology
48.1
%
| 28,924 | 49.8 % | 26,136 | 48.1 % | -9.64% |
Neuroscience
14.2
%
| 6,528 | 11.2 % | 7,717 | 14.2 % | +18.21% |
Other
12.6
%
| 7,991 | 13.8 % | 6,841 | 12.6 % | -14.39% |
Oncology
10.9
%
| 6,577 | 11.3 % | 5,915 | 10.9 % | -10.07% |
Aesthetics
9.7
%
| 5,333 | 9.2 % | 5,294 | 9.7 % | -0.73% |
Eye Care
4.4
%
| 2,701 | 4.7 % | 2,415 | 4.4 % | -10.59% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
77.1
%
| 45,713 | 78.7 % | 41,883 | 77.1 % | -8.38% |
All Other Countries
9.3
%
| 4,837 | 8.3 % | 5,042 | 9.3 % | +4.24% |
Germany
2.3
%
| 1,340 | 2.3 % | 1,266 | 2.3 % | -5.52% |
Canada
2.0
%
| 1,159 | 2.0 % | 1,076 | 2.0 % | -7.16% |
Japan
1.9
%
| 956 | 1.6 % | 1,008 | 1.9 % | +5.44% |
China
1.7
%
| 912 | 1.6 % | 950 | 1.7 % | +4.17% |
France
1.4
%
| 787 | 1.4 % | 780 | 1.4 % | -0.89% |
Spain
0.9
%
| 506 | 0.9 % | 501 | 0.9 % | -0.99% |
Italy
0.9
%
| 444 | 0.8 % | 484 | 0.9 % | +9.01% |
Australia
0.9
%
| 508 | 0.9 % | 472 | 0.9 % | -7.09% |
Brazil
0.8
%
| 430 | 0.7 % | 439 | 0.8 % | +2.09% |
United Kingdom
0.8
%
| 462 | 0.8 % | 417 | 0.8 % | -9.74% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 12-12-31 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 12-12-31 |
Robert Michael
PSD | President | 53 | 11-12-31 |
Thomas Hudson
CTO | Chief Tech/Sci/R&D Officer | 62 | 15-12-31 |
Chief Operating Officer | 60 | 12-12-31 | |
Todd D. Bosse
IRC | Investor Relations Contact | - | 21-11-30 |
Roopal Thakkar
PRN | Corporate Officer/Principal | - | 02-12-31 |
Kevin Buckbee
AUD | Comptroller/Controller/Auditor | 58 | 23-02-28 |
Perry Siatis
LAW | General Counsel | - | 22-09-30 |
Carrie Strom
PRN | Corporate Officer/Principal | - | 20-05-07 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 12-12-31 |
Edward Rapp
BRD | Director/Board Member | 66 | 12-12-31 |
Director/Board Member | 70 | 12-12-31 | |
Glenn Tilton
BRD | Director/Board Member | 75 | 12-12-31 |
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 12-12-31 |
Thomas Freyman
BRD | Director/Board Member | 69 | 20-05-07 |
Director/Board Member | 72 | 12-12-31 | |
Brett Hart
BRD | Director/Board Member | 54 | 15-12-31 |
Robert Alpern
BRD | Director/Board Member | 73 | 12-12-31 |
Robert Michael
PSD | President | 53 | 11-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,827,752,337 | 1,768,404,283 ( 96.75 %) | 57,105,354 ( 3.124 %) | 96.75 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
2,749,855 | 6.81% | 6,242,171 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Allergan Norden AB
| |
AbbVie Bahamas Ltd.
| |
AbbVie Biotechnology Ltd.
| |
AbbVie Corp.
| |
AbbVie Endocrine, Inc.
| |
AbbVie GK
| |
AbbVie International SARL
| |
AbbVie Investments SARL
| |
AbbVie Ireland NL BV
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.82% | 296B | |
+24.07% | 653B | |
+25.61% | 556B | |
-6.62% | 354B | |
+20.26% | 331B | |
+12.60% | 233B | |
+5.14% | 201B | |
-10.02% | 193B | |
-7.41% | 144B | |
-12.12% | 143B |
- Stock Market
- Equities
- ABBV Stock
- Company AbbVie Inc.